Rundu Pharma(002923)2025-01-22 08:20Financial Projections - The estimated net profit attributable to shareholders for 2024 is projected to be between 28 million and 40 million yuan, representing a year-on-year decline of 40.21% to 58.15% compared to 66.89 million yuan in the previous year[2]. - The estimated net profit after deducting non-recurring gains and losses is expected to be between 18 million and 25 million yuan, reflecting a year-on-year decrease of 42.16% to 58.35% from 43.22 million yuan last year[2]. - The basic earnings per share is forecasted to be between 0.08 yuan and 0.12 yuan, down from 0.20 yuan per share in the previous year[2]. Performance Decline Factors - The decline in performance is primarily attributed to significant decreases in sales prices of major formulation products due to industry policies and market fluctuations, particularly the national centralized procurement policy[5]. - The sales prices of key raw materials have also decreased due to domestic and international market competition, contributing to the overall decline in operating income and product profitability[5]. Financial Reporting - The financial data presented is preliminary and has not been audited by registered accountants, with detailed financial results to be disclosed in the 2024 annual report[6].